G. Argiles

Checkpoint Inhibitors in MSI-H Colorectal Cancer

G. Argiles ;

07/02/2021

Resistance Factors to IOs

G. Argiles ;

07/07/2023

Guillem Argiles, MD, Memorial Sloan Kettering Cancer Center

Videos

Mechanisms of Response to Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer

08/24/2023

G. Argiles ;

At the 2023 World Congress on Gastrointestinal Cancers, Guillen Argiles, MD, discussed the mechanisms of response to immune checkpoint inhibitors in colorectal cancer.

At the 2023 World Congress on...

08/24/2023

Oncology

Can we increase Immunogenicity in MSS Metastatic Colorectal Cancer (mCRC)?

G. Argiles ;

07/06/2019

Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC)

IntroductionREG is a multi-kinase inhibitor that improves overall survival vs placebo in refractory mCRC. However, REG adverse tolerability profile often limits its use on normal clinica...

T. Cano ;

F. Loupakis ;

Josep Tabernero , MD, PhD;

M. Rodriguez Garrote ;

F. Herrero Rivera ;

R. Goldberg ;

J. Bennouna ;

Fortunato Ciardiello ;

A. Falcone ;

E. Aranda ;

G. Argiles ;

N. Mulet Margalef ;

M. Valladares-Ayerbes ;

J. Vieitez de Prado ;

C. Gravalos ;

P. Garcia Alfonso ;

C. Santos ;

M. Tobena ;

J. Sastre ;

M. Benavides ;

07/01/2019

Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS

Introduction In the Phase III RECOURSE study, patients with metastatic colorectal cancer (mCRC) refractory to standard therapies demonstrated significantly extended overall survival and ...

Eric Van Cutsem , MD, PhD;

Alberto F. Sobrero , MD;

A. Ohtsu ;

Josep Tabernero , MD, PhD;

G. Argiles ;

R. Mayer ;

L. Vidot ;

S. Vera Moreno ;

07/01/2019